Compounds with anticancer effects. Claim 1: An arylamide derivative having the formula (1) or a stereoisomer or pharmaceutically acceptable salt thereof； wherein A is selected from the group consisting of H, halogen, C₁₋₆ alkyl,C₁₋₆ haloalkyl,perhaloalquilo C₁₋₂,C₁₋₆ hydroxyhaloalkyl,aminoquilo C₁₋₆,C₁₋₆ alkoxy,hello Coxi C₁₋₆,perhaloalcoxi C₁₋₂,C₁₋₂-Cque alkenyl alkoxy,C₁₋₆ alkylsulfonyl,arylsulfonyl, and NHR, wherein R is H or C₁₋₆ alkyl；arylamide, C₁₋₆ alkylamide,arylsulfonamide, C₁₋₆ alkylsulfonamide,and aryl； R and R each independently is selected from the group consisting of H and C₁₋₆ alkyl；z is an integer from 0 to 3； RA is a mono or bicyclic, aromatic or heteroaromatic ring system having 6 to 10 ring atoms, whereby said mono or bicyclic ring system comprises 0 to 2 or 0 to 4 nitrogen atoms in the ring, respectively, and the other atoms in the ring are carbon atoms, said ring system is not substituted or substituted one or more times, and where said substituents can be located at any appropriate location and are represented by RA； each RA is independently selected from the group consisting of halogen, C₁₋₆ alkyl,C₁₋₆ haloalkyl,perhaloalquilo C₁₋₂,hydroxy, C₁₋₆ alkoxy,No.8322；CN C (O) R COOR CONHR NRNHCOR, NHCOCF₃,NHCONHR NHCOOR OCONHR donde cada R es de modo independiente hidr geno o alquilo Cand (CH₂) ₙCHO, where n is an integer from 0 - 6； or when RA is a monocyclic ring, two adjacent RAs can be joined together to form a substituted or unsubstituted bridge； RB is an aromatic or heteroaromatic ring system having 6 atoms in the ring comprising 0 to 2 nitrogen atoms in the ring, while the other atoms in the ring are carbon atoms, said ring system is substituted one or more times, and where said substituents may be located at any appropriate location and are represented by RB； each RB is independently selected from the group consisting of halogen, C₁₋₆ alkyl,C₁₋₆ haloalkyl,perhaloalquilo C₁₋₂,hydroxy, C₁₋₆ alkoxy,No.8322；CN C (O) R COOR CONHR NRNHCOR, NHCOCF₃,
